RDB12936 - CSIV-TRE-hc-Myc-UbC-KT

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

CSIV-TRE-hc-Myc-UbC-KT (#RDB12936)

Depositor\|Developer	Miyoshi, Hiroyuki \|

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Ordering instruction.[link]

Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer.
Additional terms and conditions:
When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested.
Karasawa, S. et al., Biochem. J. 381: 307-312 (2004).

Remarks Remember that you will be working with samples containing infectious virus.
Gateway® Expression clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Ordering instruction.[link]
Terms and conditions for distribution	The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer. Additional terms and conditions: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Karasawa, S. et al., Biochem. J. 381: 307-312 (2004).
Remarks	Remember that you will be working with samples containing infectious virus. Gateway® Expression clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。
MTAに書く使用条件	本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が故三好浩之博士により開発されたことを明示する。付加的使用条件： When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Karasawa, S. et al., Biochem. J. 381: 307-312 (2004).
備考	【使用上の注意】このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。 Gateway®テクノロジーを用いた発現クローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog #	Resource name	Availability	Shipping form	Fee (non-profit org.)
RDB12936	CSIV-TRE-hc-Myc-UbC-KT	Under QC test. Please contact us.	Please contact us.	JPY 9,460 (not-for-profit academic purpose) plus cost of shipping containers, dry ice (if required) and shipping charge plus licensing fee equivalent for Gateway® expression clone

Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.
Ordering instruction of plasmids [in Japanese] [in English]